Inpharmatica and Tibotec collaborate in search for HIV/AIDs drugs
Belgium-based Tibotec Pharmaceuticals, which specialises in the development of drugs for HIV/AIDS and other infectious diseases, has signed a collaboration agreement enabling it to use UK-based Inpharmatica's Chematica technologies to identify the molecular basis for the actions of compounds shown to have anti-viral activity in cell-based assays.
Belgium-based Tibotec Pharmaceuticals, which specialises in the development of drugs for HIV/AIDS and other infectious diseases, has signed a collaboration agreement enabling it to use UK-based Inpharmatica's Chematica technologies to identify the molecular basis for the actions of compounds shown to have anti-viral activity in cell-based assays.
The Chematica technologies, including StARLITe and DrugStore, use proprietary databases to link compounds with putative molecular targets for anti-viral compounds. The financial terms of the deal were not disclosed.
Commenting on the announcement, John Lisle, ceo of Inpharmatica, said: 'This collaboration with Tibotec Pharmaceuticals follows a similar collaboration signed with Novartis in 2004 and confirms that Inpharmatica offers unique approaches to the critical problem of identifying the molecular target bioactive compounds.'